Craft

Biovica

Stock Price

KR2.2

2024-10-29

Market Capitalization

KR218.1 M

2024-10-29

Revenue

KR8.6 M

FY, 2025

Biovica Summary

Company Summary

Overview
Biovica is a biotech company that develops and commercializes blood-based biomarker assays that help to monitor cancer therapies and predict patient outcomes. It offers DiviTum, a tool that measures thymidine kinase activity (TKA), which indicates the cell proliferation rate.
Type
Public
Status
Active
Founded
2009
HQ
Uppsala, SE | view all locations
Website
http://biovica.com/
Cybersecurity rating
ESG rating
30-39 out of 100|View all ESG data
Sectors

Key People

  • Lars Holmqvist

    Lars Holmqvist, Chairman

    • Cecilia Driving

      Cecilia Driving, CFO

      LocationsView all

      2 locations detected

      • Uppsala, Uppsala län HQ

        Sweden

        Dag Hammarskjölds Väg 54B

      • Waltham, MA

        United States

        303 Wyman St #300

      Biovica Financials

      Summary Financials

      Revenue (Q3, 2026)
      kr3.3M
      Gross profit (Q3, 2026)
      kr3.4M
      Net income (Q3, 2026)
      (kr17.9M)
      Cash (Q3, 2026)
      kr88.2M
      EBIT (Q3, 2026)
      (kr17.8M)
      Enterprise value
      $134.7M

      Footer menu